Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Background and objectives: The glucagon-like peptide-1 receptor agonist liraglutide demonstrated cardiovascular and kidney benefits in the LEADER trial, particularly in participants with CKD. Design, setting, participants, & measurements: This post hoc analysis evaluated the safety of liraglutide treatment in patients with CKD in LEADER. Overall, 9340 patients were randomized to liraglutide or placebo, both in addition to standard of care. Of those, 2158 patients had CKD versus 7182 without CKD (defined as eGFR <60 versus ≥60 ml/min per 1.73 m 2 , respectively); 966 patients had macroalbuminuria and 2456 had microalbuminuria (urine albumin-creatinine ratio >300 mg/g and ≥30 to ≤300 mg/g, respectively). At baseline, the mean eGFR in patients with CKD was 46±11 ml/min per 1.73 m 2 versus 91±22 ml/min per 1.73 m 2 in those without CKD. Time to first event within event groups was analyzed using Cox regression with treatment group, baseline eGFR group, or baseline albuminuria group as fixed factors. Results: Overall, serious adverse events were more frequently recorded in patients with CKD compared with those without CKD (59% versus 50%; interaction P =0.11); however, they occurred to the same extent in those on liraglutide versus placebo. Similarly, no interaction of adverse events with randomized therapy was observed in patients with micro- or macro- versus normoalbuminuria (interaction P =0.11). Risk of severe hypoglycemia was significantly reduced with liraglutide versus placebo in patients with CKD or with micro- or macroalbuminuria (hazard ratio, 0.63 [95% CI, 0.43 to 0.91] and 0.57 [95% CI, 0.40 to 0.82], respectively). Conclusions: In LEADER, the use of liraglutide in those with CKD was safe, with no difference between patients with and without CKD. Clinical Trial registry name and registration number: ClinicalTrials.gov; NCT01179048 (https://clinicaltrials.gov/ct2/show/NCT01179048).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The recognized side effects of SGLT2 inhibition, including genital mycotic infections, volume depletion, DKA, or hypoglycemia when used with insulin or insulin secretagogues, are not greater in persons with lower levels of eGFR.471”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [471]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 2×
“There were also no reports of differences in amputations or skin gangrene with liraglutide in patients with or without CKD (see Supplemental Tables 1A, 1B, 2, 3A, and 3B), concerns that were recently raised for other glucose-lowering drugs (15,38).”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 3×
“The SGLT-2i trials EMPA-REG (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) (33), CANVAS (Canagliflozin Cardiovascular Assessment Study) (34), and CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) (15) have also reported beneficial effects on cardiov…”
BackgroundEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 2×
“Total cholesterol,mg/dl (SD) 172 (47) 172 (47) 172 (47) 172 (47) 176 (47) 176 (51) 172 (43) 172 (43) LDL, mg/dl) 90 (39) 90 (35) 90 (35) 90 (35) 94 (39) 94 (39) 90 (35) 90 (35) Systolic BP, mm Hg (SD) 136 (20) 137 (20) 136 (17) 136 (17) 141 (19) 140 (19) 133 (17) 134 (16) Diastolic BP; mm Hg (SD) 75 (11) 76 (11) 78 (1…”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · cited 3×
“Randomization was stratified according to the eGFR at screening (,30 or $30 ml/min per 1.73 m2), as calculated using the Modification of Diet in Renal Disease (MDRD) Equation (24).”
MethodInfluentialKeith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B., & Smith, D. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.6.659 · Cited by 1,684
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Self-citationU.S. Department of Health and Human (2015) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2015.1037530 · Cited by 891
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648
Management of Diabetic Foot Ulcers
Alexiadou, K., & Doupis, J. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0004-9 · Cited by 565
Frequency of hypoglycemia and its significance in chronic kidney disease
Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., & Fink, J. C. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00800209 · Cited by 423 · cited 2×
“This hypoglycemia benefit with liraglutide is of clinical interest because CKD is a significant risk factor for hypoglycemia development and the choice of alternative glucose-lowering drugs is restricted (36).”
BackgroundCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
(2017) · New England Journal of Medicine · doi:10.1056/nejmc1712572 · Cited by 415
Cefalu, W. T., Kaul, S., Gerstein, H. C., Holman, R. R., Zinman, B., Skyler, J. S., Green, J. B., Buse, J. B., Inzucchi, S. E., Leiter, L. A., et al. (2018) · Diabetes Care · doi:10.2337/dci17-0057 · Cited by 363
Self-citationCardiovascular Complications of Diabetic Kidney Disease
Pálsson, R., & Patel, U. D. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.003 · Cited by 292
The effect of chronic renal failure on drug metabolism and transport
Dreisbach, A. W., & Lertora, J. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.8.1065 · Cited by 251
Marso, S. P., Poulter, N. R., Nissen, S. E., Nauck, M. A., Zinman, B., Daniels, G. H., Pocock, S., Steinberg, W. M., Bergenstal, R. M., Mann, J. F. E., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.07.012 · Cited by 245
Self-citationDavies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E. (2016) · Diabetes Care · doi:10.2337/dc14-2883 · Cited by 235
Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide
Jacobsen, L. V., Hindsberger, C., Robson, R., & Zdravkovic, M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03536.x · Cited by 215
Papademetriou, V., Lovato, L., Doumas, M., Nylen, E., Mottl, A., Cohen, R. M., Applegate, W. B., Puntakee, Z., Yale, J. F., & Cushman, W. C. (2015) · Kidney International · doi:10.1038/ki.2014.296 · Cited by 210
Effect of renal impairment on the pharmacokinetics of exenatide
Linnebjerg, H., Kothare, P. A., Park, S., Mace, K., Reddy, S., Mitchell, M., & Lins, R. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02890.x · Cited by 198
Interactions between kidney disease and diabetes: dangerous liaisons
Pecoits-Filho, R., Abensur, H., Betônico, C. C. R., Machado, A. D., Parente, E. B., Queiroz, M., Salles, J. E. N., Titan, S., & Vencio, S. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0159-z · Cited by 171
Groop, P., Cooper, M. E., Perkovic, V., Hocher, B., Kanasaki, K., Haneda, M., Schernthaner, G., Sharma, K., Stanton, R. C., Toto, R., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13041 · Cited by 149
Mann, J. F. E., Fonseca, V., Mosenzon, O., Raz, I., Goldman, B., Idorn, T., von Scholten, B. J., Poulter, N. R., & The LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Circulation · doi:10.1161/circulationaha.118.036418 · Cited by 147 · cited 5×
“with CKD, in addition to those without CKD, at baseline (20,21).”
BackgroundInfluentialSelf-citationDhatariya, K., Bain, S. C., Buse, J. B., Simpson, R., Tarnow, L., Kaltoft, M. S., Stellfeld, M., Tornøe, K., Pratley, R. E., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc18-1094 · Cited by 141 · cited 4×
“73 m(2) (SD) 46 (11) 46 (11) 91 (22) 91 (22) 74 (30) 75 (29) 84 (26) 84 (26)”
BackgroundResultInfluentialThe effect of liraglutide on renal function: A randomized clinical trial
von Scholten, B. J., Persson, F., Rosenlund, S., Hovind, P., Faber, J., Hansen, T. W., & Rossing, P. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12808 · Cited by 105
Scheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102 · cited 3×
“Diabetes duration, yr (SD) 15 (9) 15 (9) 12 (8) 12 (8) 14 (8) 14 (8) 12 (8) 12 (8) Prior stroke/MI, N (%) 437 (39) 424 (41) 1566 (44) 1567 (43) 683 (41) 708 (41) 1280 (44) 1239 (44) History of MI 325 (29) 294 (28) 1139 (32) 1106 (31) 506 (30) 500 (29) 935 (32) 866 (31)”
Idorn, T., Knop, F. K., Jørgensen, M. B., Jensen, T., Resuli, M., Hansen, P. M., Christensen, K. B., Holst, J. J., Hornum, M., & Feldt-Rasmussen, B. (2016) · Diabetes Care · doi:10.2337/dc15-1025 · Cited by 96
Self-citationKelly, M. S., Lewis, J., Huntsberry, A. M., Dea, L., & Portillo, I. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1549459 · Cited by 94
Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
Ye, Y., Zhao, C., Liang, J., Yang, Y., Yu, M., & Qu, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01517 · Cited by 87
Diabetes Management Issues for Patients With Chronic Kidney Disease
Cavanaugh, K. L. (2007) · Clinical Diabetes · doi:10.2337/diaclin.25.3.90 · Cited by 82
Davies, M., Chatterjee, S., & Khunti, K. (2016) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s82008 · Cited by 75
Liraglutide and Glycaemic Outcomes in the LEADER Trial
Zinman, B., Nauck, M. A., Bosch‐Traberg, H., Frimer‐Larsen, H., Ørsted, D. D., & Buse, J. B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0524-z · Cited by 60
Cosmo, S. D., Viazzi, F. C., Pacilli, A., Giorda, C. B., Ceriello, A., Gentile, S., Russo, G. T., Rossi, M. C., Nicolucci, A., Guida, P., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv101 · Cited by 57
Penno, G., Garofolo, M., & Prato, S. D. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.01.001 · Cited by 57
Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects
Satirapoj, B. (2017) · Kidney Diseases · doi:10.1159/000471765 · Cited by 42
Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial
HRAMIAK, I. M., Vilsbøll, T., Gumprecht, J., Silver, R., Hansen, T., Pettersson, J., & Wilding, J. P. H. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.08.126 · Cited by 5
Research works printed but not linked: 1
- US Department of Health and Human Services: Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Determining the extent of safety data collection needed in late-stage premarket and postapproval clinical investigations - Guidance for Industry, 2016. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm291158.pdf. Accessed February 12, 2020 [DOI] [PubMed]
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Obesity and chronic kidney disease
Jiang, Z., Wang, Y., Zhao, X., Cui, H., Han, M., Ren, X., Gang, X., & Wang, G. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00179.2022 · Cited by 267
Rossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad009 · Cited by 242
Self-citationMann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30313-2 · Cited by 157
Self-citation
Metadata
- Authors
- Mann, J. F. E., Fonseca, V. A., Poulter, N. R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., Mosenzon, O., & on behalf of the LEADER Trial Investigators
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Tulane University (US)
- Imperial College London (GB)
- Hadassah Medical Center (IL)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S, Søborg, Denmark
- Corresponding author
- Mann, Johannes F.E.
- ORCID
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2020-03-04
- Volume
- 15
- Issue
- 4
- Pages
- 465-473
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC7133133
- OpenAlex
- W3010392113
- Cited by
- 50
- References
- 39
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 8 · 2021: 12 · 2020: 5
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- liraglutide, type 2 diabetes, chronic kidney disease, GLP-1 receptor agonists, drug safety, LEADER trial, albuminuria, microalbuminuria, macroalbuminuria, hypoglycemia, serious adverse events, EGFR, cardiovascular outcomes, renal outcomes, drug interactions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glomerular Filtration Rate, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Kidney, Male, Middle Aged, Time Factors, Biomarkers, Treatment Outcome, Renal Insufficiency, Chronic, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.